PDCD1 and neoplasm: In another study, Lee et al. associated regulatory T cells and intratumoral CD11b+ monocytes with this immunosuppressive environment in in vivo tumor models of liver metastases in immunocompetent mice, suggesting that combining anti-CTLA4 or EZH2 inhibitors with anti-PD-1 could improve clinical results [64].